Oct. 6 at 6:50 PM
$MTNB added more
Low-float biotech gearing up for potential breakout.
Lead drug MAT2203: Oral amphotericin B — could revolutionize antifungal treatment if data stays strong.
LNC delivery tech: Matinas’ lipid nanocrystal platform could attract partnerships or licensing deals from bigger pharma.
Recent funding:
$3.3M preferred + warrants secures runway and removes near-term dilution fears.
Setup: Tight float + strong chart base around
$1.80–
$1.90. Above
$2.20 = momentum trigger.
Catalysts ahead: Clinical updates, shareholder vote, or partnership news.
Targets:
$3–
$5 near term,
$6–
$8+ on clinical success or deal.
Speculative, but risk/reward looks prime for a biotech swing. #MTNB #biotech #lowfloat #LNCplatform #momentum
